Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cingulate Inc WT (CINGW)

Cingulate Inc WT (CINGW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,530 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CINGW with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 05/08/24 [--]
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0113 +92.92%
on 04/10/24
0.0299 -27.09%
on 04/15/24
+0.0107 (+96.40%)
since 04/02/24
3-Month
0.0088 +147.73%
on 02/07/24
0.0350 -37.71%
on 03/11/24
+0.0068 (+45.33%)
since 02/02/24
52-Week
0.0025 +772.00%
on 10/19/23
0.4400 -95.05%
on 05/26/23
-0.0592 (-73.09%)
since 05/02/23

Most Recent Stories

More News
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc....

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year

KC Business Veteran, Two-Time Award Winner, Helped Lead Cingulate to 2021 IPO...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

CTx-2103 (buspirone) is the Third Candidate Using Cingulate’s Proprietary Precision Timed Release™ Drug Delivery Platform Technology for Once-daily Dosing...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational

KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Cingulate to Present at H.C. Wainwright Global Investment Conference

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

Announcement of First Dosage for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Releaseâ„¢ Platform (PTRâ„¢) ...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Cingulate Presents at NobleCon18

KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)
Cingulate Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Clinical and Business Update

Completed Initial Public Offering, Raising Gross Proceeds of $25.0 Million Expedited Clinical Program for CTx-1301 Expected to Reduce Capital Requirements...

CINGW : 0.0218 (-0.91%)
CING : 0.9646 (-13.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar